Eton Pharmaceuticals, Inc ("Eton" or "the Company") (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced preliminary results from a randomized, double-blind, placebo-controlled pilot study evaluating ET-700, its investigational extended-release zinc acetate formulation being developed to treat Wilson disease.

ET-700 demonstrated a lower rate of drug related adverse events than GALZIN, with participants who received ET-700 reporting a single gastrointestinal-related adverse event. In comparison, 8 out of 12 participants receiving GALZIN reported 17 adverse events. Participants who received placebo reported 3 treatment related adverse events in 3 of the 12 participants. No serious adverse events were reported in the study. The estimated rate of treatment related gastrointestinal side effects was 0.30 per 100 participant-days for ET-700, compared with 5.35 for GALZIN and 0.89 for the placebo.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.